XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Summary of Financial Information for Our Segments

The following tables present our U.S. and International disaggregated net sales. Intersegment sales are eliminated in consolidation.

			Three Months Ended September 30,
			2023												2022
(in millions)			U.S.			International			Total						U.S.			International			Total
Infusion Therapies and Technologies			$	570		$	433		$	1,003					$	567		$	389		$	956
Advanced Surgery			139			116			255						141			106			247
Medical Products and Therapies			709			549			1,258						708			495			1,203
Care and Connectivity Solutions			317			126			443						339			117			456
Front Line Care			234			67			301						209			70			279
Healthcare Systems and Technologies			551			193			744						548			187			735
Injectables and Anesthesia			195			156			351						173			152			325
Drug Compounding			—			229			229						—			200			200
Pharmaceuticals			195			385			580						173			352			525
Chronic Therapies1			233			688			921						236			698			934
Acute Therapies1			66			122			188						57			109			166
Kidney Care			299			810			1,109						293			807			1,100
Other1			12			5			17						36			10			46
Total Baxter			$	1,766		$	1,942		$	3,708					$	1,758		$	1,851		$	3,609

			Nine Months Ended September 30,
			2023												2022
(in millions)			U.S.			International			Total						U.S.			International			Total
Infusion Therapies and Technologies			$	1,654		$	1,264		$	2,918					$	1,672		$	1,157		$	2,829
Advanced Surgery			433			340			773						428			310			738
Medical Products and Therapies			2,087			1,604			3,691						2,100			1,467			3,567
Care and Connectivity Solutions			926			381			1,307						991			359			1,350
Front Line Care			681			230			911						618			237			855
Healthcare Systems and Technologies			1,607			611			2,218						1,609			596			2,205
Injectables and Anesthesia			550			437			987						494			467			961
Drug Compounding			—			665			665						—			613			613
Pharmaceuticals			550			1,102			1,652						494			1,080			1,574
Chronic Therapies1			689			2,041			2,730						675			2,069			2,744
Acute Therapies1			194			370			564						194			348			542
Kidney Care			883			2,411			3,294						869			2,417			3,286
Other1			56			17			73						98			31			129
Total Baxter			$	5,183		$	5,745		$	10,928					$	5,170		$	5,591		$	10,761

1In connection with our segment change in the third quarter of 2023, we made the following reclassifications of prior period sales amounts to conform to the current period presentation. We reclassified $16 million of sales from the first half of 2023 and $8 million and $23 million for the three and nine months ended September 30, 2022, respectively, from Chronic Therapies to Acute Therapies. Additionally, in connection with the reclassification of our BPS business to discontinued operations during the second quarter of 2023, we reclassified $2 million of contract manufacturing revenues from the first quarter of 2023 and $8 million and $26 million for the three and nine months ended September 30, 2022, respectively, from BPS to Other (within continuing operations), as the related manufacturing facility was not part of that divestiture transaction.

Revenue from External Customers by Geographic Areas

Our net sales are attributed to the following geographic regions based on the location of the customer.

			Three Months Ended September 30,												Nine Months Ended September 30,
			2023						2022						2023						2022
United States			$	1,766					$	1,758					$	5,183					$	5,170
Emerging markets1			852						820						2,447						2,355
Rest of world2			1,090						1,031						3,298						3,236
Total Baxter			$	3,708					$	3,609					$	10,928					$	10,761

1 Emerging markets include sales from our operations in Eastern Europe, the Middle East, Africa, Latin America and Asia (except for Japan).

2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia and New Zealand.

Operating Income to Income Before Income Taxes Reconciliation

The following table presents our segment operating income and reconciliations of segment operating income to income (loss) from continuing operations before income taxes.

			Three months ended September 30,									Nine months ended September 30,
(in millions)			2023			2022						2023			2022
Medical Products and Therapies			$	245		$	257					$	706		$	703
Healthcare Systems and Technologies			115			108						327			367
Pharmaceuticals			108			82						284			295
Kidney Care			96			103						208			307
Other			6			17						19			52
Total			570			567						1,544			1,724
Unallocated corporate costs			(5)			1						(51)			(41)
Intangible asset amortization expense			(162)			(168)						(481)			(578)
Long-lived asset impairments			(267)			(332)						(267)			(332)
Legal matters			(13)			—						(13)			—
Goodwill impairments			—			(2,785)						—			(2,785)
Business optimization items			(81)			(73)						(508)			(196)
Acquisition and integration items			(2)			(4)						(2)			(193)
Loss on product divestiture arrangement			—			(54)						—			(54)
Separation-related costs			(77)			—						(123)			—
European Medical Devices Regulation			(14)			(12)						(38)			(35)
Product-related items			—			(20)						—			(43)
Total operating income (loss)			(51)			(2,880)						61			(2,533)
Interest expense, net			128			104						369			278
Other (income) expense, net			(7)			61						33			1
Loss from continuing operations before income taxes			$	(172)		$	(3,045)					$	(341)		$	(2,812)

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph a
-SubTopic 10
-Topic 280
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration